Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Pipeline Review, H2 2018
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Lysophosphatidic Acid Receptor 1%li%Pipeline Review, H2 2018'; Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 8 molecules.
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a group known as EDG receptors. EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, and smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis, and tumor cell invasion.
The report 'Lysophosphatidic Acid Receptor 1%li%Pipeline Review, H2 2018' outlays comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 5 and 1 respectively.
Report covers products from therapy areas Gastrointestinal, Metabolic Disorders, Musculoskeletal Disorders, Respiratory, Genito Urinary System And Sex Hormones, Immunology, Male Health and Toxicology which include indications Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Benign Prostatic Hyperplasia, Diabetic Nephropathy, Diabetic Neuropathy, Diarrhea, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Plaque Psoriasis (Psoriasis Vulgaris), Pulmonary Fibrosis, Radiation Toxicity (Radiation Sickness and Acute Radiation Syndrome).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Lysophosphatidic Acid Receptor 1%li%Pipeline Review, H2 2018'; Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 8 molecules.
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a group known as EDG receptors. EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, and smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis, and tumor cell invasion.
The report 'Lysophosphatidic Acid Receptor 1%li%Pipeline Review, H2 2018' outlays comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 5 and 1 respectively.
Report covers products from therapy areas Gastrointestinal, Metabolic Disorders, Musculoskeletal Disorders, Respiratory, Genito Urinary System And Sex Hormones, Immunology, Male Health and Toxicology which include indications Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Benign Prostatic Hyperplasia, Diabetic Nephropathy, Diabetic Neuropathy, Diarrhea, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Plaque Psoriasis (Psoriasis Vulgaris), Pulmonary Fibrosis, Radiation Toxicity (Radiation Sickness and Acute Radiation Syndrome).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)
- The report reviews Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Overview
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Novo Nordisk AS
Ono Pharmaceutical Co Ltd
RxBio Inc
Takeda Pharmaceutical Co Ltd
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Drug Profiles
BMS-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-2090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPGN-696 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7300243 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rx-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize LPA1 for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-615 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Dormant Products
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Discontinued Products
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Product Development Milestones
Featured News & Press Releases
Sep 28, 2011: RxBio Receives $15m BARDA Contract For Development Of Rx100 To Protect Against Radiation
May 11, 2011: Amira To Present Preclinical Data On AM152 At Annual Meeting Of American Thoracic Society
May 02, 2011: Amira Pharmaceuticals Completes Phase I Clinical Study Of AM152
Apr 19, 2011: Amira Receives Orphan Drug Status For AM152 In Idiopathic Pulmonary Fibrosis
Oct 28, 2010: Amira Initiates Phase I Clinical Trial For AM152
Sep 27, 2010: Amira Submits AM152 IND To FDA For Potential Use In Fibrotic Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Overview
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Novo Nordisk AS
Ono Pharmaceutical Co Ltd
RxBio Inc
Takeda Pharmaceutical Co Ltd
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Drug Profiles
BMS-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-2090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPGN-696 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7300243 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rx-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize LPA1 for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-615 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Dormant Products
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Discontinued Products
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Product Development Milestones
Featured News & Press Releases
Sep 28, 2011: RxBio Receives $15m BARDA Contract For Development Of Rx100 To Protect Against Radiation
May 11, 2011: Amira To Present Preclinical Data On AM152 At Annual Meeting Of American Thoracic Society
May 02, 2011: Amira Pharmaceuticals Completes Phase I Clinical Study Of AM152
Apr 19, 2011: Amira Receives Orphan Drug Status For AM152 In Idiopathic Pulmonary Fibrosis
Oct 28, 2010: Amira Initiates Phase I Clinical Trial For AM152
Sep 27, 2010: Amira Submits AM152 IND To FDA For Potential Use In Fibrotic Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Novo Nordisk AS, H2 2018
Pipeline by Ono Pharmaceutical Co Ltd, H2 2018
Pipeline by RxBio Inc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Novo Nordisk AS, H2 2018
Pipeline by Ono Pharmaceutical Co Ltd, H2 2018
Pipeline by RxBio Inc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Bristol-Myers Squibb Co
Novo Nordisk AS
Ono Pharmaceutical Co Ltd
RxBio Inc
Takeda Pharmaceutical Co Ltd
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Bristol-Myers Squibb Co
Novo Nordisk AS
Ono Pharmaceutical Co Ltd
RxBio Inc
Takeda Pharmaceutical Co Ltd
